Schedule II & RFK ·
CJC-1295 and ipamorelin are growth hormone secretagogues commonly used in research and, historically, in compounding pharmacy practice. Like BPC-157 and TB-500, they were effectively restricted through the 2023 FDA bulk substance review. In the 2025–2026 HHS peptide policy review they have been named among peptides for which FDA bulks list reconsideration has been requested. Scientific advisory committee discussions have focused on the safety data supporting their use, and several stakeholder groups have submitted public comments urging updated regulatory treatment. No formal relisting has occurred as of April 2026, but the topic remains actively discussed.
Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.